ABBOTT LABORATORIES Comprehensive Income 2008-2026 | ABT
Beta
What is comprehensive income?
Comprehensive income includes net income plus other comprehensive items like foreign currency adjustments and unrealized investment gains or losses.
What is ABBOTT LABORATORIES's current comprehensive income?
ABBOTT LABORATORIES (ABT) annual comprehensive income for 2025 was $8.43B, a 36.79% decline from 2024. ABBOTT LABORATORIES comprehensive income for the quarter ending March 31, 2026 was $766.0M.
What was ABBOTT LABORATORIES's comprehensive income in 2024?
ABBOTT LABORATORIES annual comprehensive income for 2024 was $13.34B, a 124.68% increase from 2023.
What was ABBOTT LABORATORIES's comprehensive income in 2023?
ABBOTT LABORATORIES annual comprehensive income for 2023 was $5.93B, a 18.21% decline from 2022.
What is ABBOTT LABORATORIES's 5-year comprehensive income CAGR?
ABBOTT LABORATORIES comprehensive income grew at a compound annual growth rate (CAGR) of 16.00% from FY2020 to FY2025, going from $4.01B to $8.43B over 5 years.
Comprehensive Income History
Year-over-year comparison from 10-K annual reports
Key Statistics
Trend Direction
Stable
CAGR+16.0%
FY2020
$4.01B
→
FY2025
$8.43B
080910111213141516171819202122232425
5 years selected
Comprehensive Income History
| Period | Value | Change | Source |
|---|---|---|---|
| FY2025 | $8.43B | -36.8% | 10-K |
| FY2024 | $13.34B | +124.7% | 10-K |
| FY2023 | $5.93B | -18.2% | 10-K |
| FY2022 | $7.26B | -5.1% | 10-K |
| FY2021 | $7.64B | +90.4% | 10-K |
| FY2020 | $4.01B | +42.9% | 10-K |
| FY2019 | $2.81B | +138.8% | 10-K |
| FY2018 | $1.18B | -23.1% | 10-K |
| FY2017 | $1.53B | +92.3% | 10-K |
| FY2016 | $795.0M | -70.5% | 10-K |
| FY2015 | $2.69B | +455.5% | 10-K |
| FY2014 | $-757.0M | -124.0% | 10-K |
| FY2013 | $3.15B | -36.6% | 10-K |
| FY2012 | $4.97B | +42.0% | 10-K |
| FY2011 | $3.50B | +45.4% | 10-K |
| FY2010 | $2.40B | -69.0% | 10-K |
| FY2009 | $7.76B | +374.9% | 10-K |
| FY2008 | $1.64B | - | 10-K |
Company: ABBOTT LABORATORIESTicker: ABTSector: HealthcareIndustry: Pharmaceutical PreparationsView company profile →